Back to News
Market Impact: 0.2
Abbott's Amulet 360 Receives CE Mark For Stroke Prevention In Non-Valvular AFib
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct LaunchesCompany Fundamentals
Abbott Laboratories received CE Mark approval for its Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation device intended to reduce stroke risk in patients with non-valvular atrial fibrillation. The regulatory milestone supports commercialization of a new cardiovascular offering, which is modestly positive for sentiment though unlikely to be market-moving on its own.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABT0.40
More News
- How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
- History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.
- Musk says Terrafab chip factory could outperform rivals despite challenges
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Will Warner Bros. kill Skydance — or will David Ellison kill Warner Bros?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant